Alexandra Tachtsidi

Alexandra Tachtsidi

Auto-generated profile, based on publicly available information

Alexandra Tachtsidi

Genethon; 91000 Evry, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2019 in Genome Research
Verified
Journal Article
Open access
PDF file
NFNicola Festuccia
Nicola Festuccia
NONick Owens
Nick Owens
TPThaleia Papadopoulou
Thaleia Papadopoulou
IGInma Gonzalez
Inma Gonzalez
ATAlexandra Tachtsidi
Alexandra Tachtsidi
PNPablo Navarro
Pablo Navarro
Mitotic bookmarking transcription factors (BFs) maintain the capacity to bind to their targets during mitosis, despite major rearrangements of the chromatin. While they were thought to propagate gene regulatory information through mitosis by statically occupying their DNA targets, it has recently become clear that BFs are highly dynamic in mitotic cells. This represents both a technical and a conceptual challenge to study and understand the function of BFs: First, formaldehyde has been suggested to be unable to efficiently capture these transient interactions, leading to profound contradictions in the literature; and second, if BFs are not permanently bound to their targets during mitosis, it becomes unclear how they convey regulatory information to daughter cells. Here, comparing formaldehyde to alternative fixatives we clarify the nature of the chromosomal association of previously proposed BFs in embryonic stem cells: While ESRRB can be considered as a canonical BF that binds at selected regulatory regions in mitosis, SOX2 and POU5F1 (also known as OCT4) establish DNA sequence-independent interactions with the mitotic chromosomes, either throughout the chromosomal arms (SOX2) or at pericentromeric regions (POU5F1). Moreover, we show that ordered nucleosomal arrays are retained during mitosis at ESRRB bookmarked sites, whereas regions losing transcription factor binding display a profound loss of order. By maintaining nucleosome positioning during mitosis, ESRRB might ensure the rapid post-mitotic re-establishment of functional regulatory complexes at selected enhancers and promoters. Our results provide a mechanistic framework that reconciles dynamic mitotic binding with the transmission of gene regulatory information across cell division.

26 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
GPGiulia Pavani
Giulia Pavani
AFAnna Fabiano
Anna Fabiano
MLMarine Laurent
Marine Laurent
FAFatima Amor
Fatima Amor
ECErika Cantelli
Erika Cantelli
MAMario Amendola
Mario Amendola
β-thalassemias (β-thal) are a group of blood disorders caused by mutations in the β-globin gene (HBB) cluster. β-globin associates with α-globin to form adult hemoglobin (HbA, α2β2), the main oxygen-carrier in erythrocytes. When β-globin chains are absent or limiting, free α-globins precipitate and damage cell membranes, causing hemolysis and ineffective erythropoiesis. Clinical data show that severity of β-thal correlates with the number of inherited α-globin genes (HBA1 and HBA2), with α-globin gene deletions having a beneficial effect for patients. Here, we describe a novel strategy to treat β-thal based on genome editing of the α-globin locus in human hematopoietic stem/progenitor cells (HSPCs). Using CRISPR/Cas9, we combined 2 therapeutic approaches: (1) α-globin downregulation, by deleting the HBA2 gene to recreate an α-thalassemia trait, and (2) β-globin expression, by targeted integration of a β-globin transgene downstream the HBA2 promoter. First, we optimized the CRISPR/Cas9 strategy and corrected the pathological phenotype in a cellular model of β-thalassemia (human erythroid progenitor cell [HUDEP-2] β0). Then, we edited healthy donor HSPCs and demonstrated that they maintained long-term repopulation capacity and multipotency in xenotransplanted mice. To assess the clinical potential of this approach, we next edited β-thal HSPCs and achieved correction of α/β globin imbalance in HSPC-derived erythroblasts. As a safer option for clinical translation, we performed editing in HSPCs using Cas9 nickase showing precise editing with no InDels. Overall, we described an innovative CRISPR/Cas9 approach to improve α/β globin imbalance in thalassemic HSPCs, paving the way for novel therapeutic strategies for β-thal.

26 November 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
GHGiulia Hardouin
Giulia Hardouin
PMPierre Martinucci
Pierre Martinucci
SSSamantha Scaramuzza
Samantha Scaramuzza
PAPanagiotis ANTONIOU
Panagiotis ANTONIOU
FCFederico Corradi
Federico Corradi
AMAnnarita Miccio
Annarita Miccio
Gene therapy has emerged as a promising curative treatment for β-hemoglobinopathies, the most common genetic disorders worldwide. However, current approved approaches still have some limitations in terms of safety and efficacy. Here, we used highly processive adenine base editor (ABE) variants to precisely correct some of the most prevalent and severe β-thalassemia–causing mutations in the β-globin–encoding HBB gene, including CD39 and IVS2-1, using NRCH-ABE8e and SpRY-ABE8e, respectively. More than 90% of editing of hematopoietic stem and progenitor cells (HSPCs) led to improved β-globin expression in their erythroid progeny and persistent correction of both β-thalassemia and sickle cell–β-thalassemia phenotypes. The safety of this strategy was confirmed in HSPCs in vitro and in vivo through the absence of gene dysregulation and any meaningful impact on the DNA mutational burden, RNA deamination, β-globin gene locus integrity, and the clonality of the HSPC graft, as assessed by RNA sequencing, whole-exome sequencing, long-read sequencing, and human HSPC transplantation in immunodeficient mice. Overall, these preclinical studies suggest that base editing–mediated gene correction may be a safe and effective strategy for treating β-hemoglobinopathies.

3 April 2026
Verified
Thesis
Closed access
ATAlexandra Tachtsidi
Alexandra Tachtsidi
Organisation nucléaire et régulation d’expression des gènes dans les cellules souches embryonnaires murines par les longs ARN non-codants: Le noyau est extrêmement structuré et il a été démontré que les longs ARN non-codants (lncRNAs) sont impliqués dans l'organisation nucléaire en établissant la compartimentation nucléaire, par les domaines sous-nucléaires ou des interactions à longue portée dans l'espace nucléaire. Une approche robuste pour l'identification de telles molécules fait toutefois défaut. Nous avons mis en place une approche expérimentale permettant d'identifier les lncRNAs «structurels» à l'échelle du génome. Basé sur la propriété biochimique de certains lncRNAs à résister l’extraction de la matrice nucléaire, quand l’ADN et les molécules solubles sont enlevés, nous avons effectué des préparations de matrice nucléaire en utilisant des cellules souches embryonnaires murines, purifié la fraction d’ARN et exploré ses constituants par RNA-seq. Nous avons identifié des transcrits (non-extracted RNAs, nextRNAs) potentiellement impliqués dans l'organisation fonctionnelle du noyau. Nous avons notamment détecté des transcrits précédemment pas annotées et axé notre travail sur deux gènes: NextC1 (Next Candidate 1) et 2. Nous les avons caractérisées au niveau fonctionnel et phénotypique en explorant leur profil d’expression dans différents contextes de culture et lignées cellulaires dérivées de l'embryon. Leur localisation subcellulaire a été évaluée par RNA-FISH. Des analyses de perte et de gain de fonction ont été effectuées en ciblant leurs régions promotrices avec le système CRISPR/Cas9 et les systèmes dérivés de CRISPR pour l'inhibition ou l'activation de la transcription. Nombreuses de ces analyses fonctionnelles ont ensuite été soumis à RNA-seq et une analyse de données intégrative est en cours.

17 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GSgiulia scalisi
giulia scalisi
ASAboud Sakkal
Aboud Sakkal
LLLaurie Lacombe
Laurie Lacombe
FSFrancesco Sarnari
Francesco Sarnari
MRMarine Rouillon
Marine Rouillon
MAMario Amendola
Mario Amendola
Ex vivo genome editing of human hematopoietic stem and progenitor cells (HSPCs) requires targeted integration strategies that support large therapeutic DNA payloads while preserving stem cell fitness. Although CRISPR/Cas9-mediated homology-directed repair using AAV donors is effective, it is constrained by limited cargo capacity and adverse effects on long-term HSPCs function. Integrase-defective lentiviral vectors (IDLVs) offer an alternative donor platform, yet their precise and controlled genomic integration remains inefficient. Here, we describe TILV (Targeted Integration of Lentiviral Vector), a CRISPR-assisted knock-in strategy that exploits Cas9-mediated linearization of episomal IDLV DNA to expose a single homology arm and engage homology-mediated end-joining repair pathways. TILV enables precise, directional and seamless integration of transgenes in multiple loci, enabling constitutive or physiological expression. Using single-cell clonal analyses and targeted long-read sequencing, we define the molecular features of TILV-mediated integration and demonstrate preferential use of CRISPR-linearized episomal substrates. TILV supports accurate insertion of large therapeutic transgenes, without compromising HSPC viability or multilineage potential. We further show that transient modulation of DNA repair pathway, in combination with extended homology arms, enhances integration efficiency and junctional precision. Importantly, optimized TILV enables targeted integration in phenotypically defined long-term HSPCs, highlighting its potential for scalable and durable gene therapy.